MedTrace Logo

Probiotic Supplement Versus Placebo for the Treatment of Patients With Non-alcoholic Fatty Liver Disease

NCT06491342 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2025-07-25

No results posted yet for this study

Summary

Probiotic supplement versus placebo for the treatment of patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial

Conditions

  • Fatty Liver, Nonalcoholic

Interventions

DIETARY_SUPPLEMENT

Probiotic

Probiotic-Lactobacillus Zeae and Lactobacillus reuteri

DIETARY_SUPPLEMENT

Placebo

placebo

Sponsors & Collaborators

  • Chiang Mai University

    collaborator OTHER

  • Thailand Institute of scientific and technological research

    collaborator UNKNOWN

  • Phramongkutklao College of Medicine and Hospital

    lead OTHER

Principal Investigators

  • Natchaporn Noppacroh · phramongkutklao

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-25
Primary Completion
2025-04-22
Completion
2025-05-28

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06491342 on ClinicalTrials.gov